Cell Line Development Market is Segmented By Types of Cell Lines (Primary Cell Lines, Continuous Cell Lines, Hybridomas, Recombinant Cell Lines), By Application(Bioproduction, Tissue Engineering Regenerative Medicines, Toxicity Testing, Research, Drug Discovery ), By Source(Mammalian Cell Lines, Non –Mammalian Cell Line), By Product(Reagent and Media, Equipment, Finished Cells, Others), By End-User ( Academics and Research Institutes, Biotech Companies, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Cell Line Development Market Overview
Cell line Development Market is Predicted to reach at a CAGR of 12.13% during the forecast period (2024-2031). The cell line is a well-established cell culture in which the cells multiply in the appropriate growth media and space. Distinct types of cells are used to create different cell lines. Cell lines allow for gradual changes in cell structure, physiology, and genetic makeup in a controlled setting.
Cell Line Development Market Summary and Scope
Metrics |
Details |
Market CAGR |
12.13% |
Segments Covered |
By Types, By Application, By Source, By Product, By End-User, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
Cell Line Development Market Dynamics and Trends
The increasing use of regenerative treatments, rising cancer occurrence around the world, and soaring R&D investments by pharmaceutical and biotechnology businesses are all contributing to the cell line development market's growth. Moreover, ongoing research in drug discovery efforts is expected to fuel market expansion during the forecast period.
The increase in prevalance of cancer cases in the market will drive the market growth
Because the global cancer burden is expanding, cancer treatments must be tailored to regional and national goals. According to the WCRF, there were an estimated 18 million cancer cases worldwide in 2018, with 9.5 million males and 8.5 million women affected.
Lung and breast cancers are the most frequent cancers, accounting for 12.3 percent of all new cases diagnosed in 2018. According to the WCRF, colorectal malignancy was the third most frequent cancer in 2018, with 1.8 million new cases.
Many factors contribute to the rising cancer burden, including population increase and aging and the changing prevalence of various cancers linked to social and economic developments. Cancer has also been linked to one's way of life.
The figures above show that cancer has a high global burden, which is projected to drive the cell line development market extension. There is a growing desire for innovative therapies to treat cancer. Regenerative medicines can replace or mend tissues and organs that have been destroyed by aging, disease, or trauma and assist in normalizing congenital abnormalities. Over the previous quarter-century, a tissue engineering industry has emerged, which has expanded into the broader field of regenerative medicine. Engineering sciences are being used to produce clinical therapies for the maintenance, repair, replacement, and augmentation of biological processes in regenerative medicine, which is a fast-emerging interdisciplinary subject. The generation of cell lines is an essential and inextricable aspect of this area since it aids in the understanding of how to treat a wide range of medical disorders, from broken bones to neurological diseases. Regenerative medicines also use cell-based models, which could aid researchers in developing early-intervention treatments for degenerative diseases and catastrophic injuries. As a result, the growing use of regenerative treatments will fuel demand for cell line development in the future years. This contributes to the growth of the global cell line development market.
High capital investment and complexity associated with the cell development process is likely to hamper the market growth
Every stage of the CLD workflow can be arduous and time-consuming, limiting the cell line development market's growth. Furthermore, the possibility of contamination, misidentification, and random alternations in cell line creation impede the market's expansion.
COVID-19 Impact Analysis on Cell Line Development Market
Over the projection period, the increased prevalence of COVID-19 is expected to impact cell line development market growth. The majority of pharmaceutical businesses have suffered considerable losses due to the coronavirus outbreak, which has hampered the cell line development market. The COVID-19 pandemic has had a remarkable influence on the global economy; this has significantly impacted production processes and demand across multiple verticals and disrupted the supply chain. During the initial phase of COVID, many businesses ceased manufacturing and supply operations. However, the current COVID-19 situation is expected to return to normalcy as medical professionals and health authorities in the countries take the necessary steps to combat the virus. Furthermore, pharmaceutical companies and research institutions worldwide have focused their efforts on developing a vaccine for COVID-19, putting the development of other therapeutics on hold.
Cell Line Development Segmentation Analysis
The mammalian cell development segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Mammalian cells are estimated to account for the majority of the market share over the forecast period. The increased usage of a mammalian source to manufacture monoclonal antibodies is a major factor driving the cell line development market (mAbs). The need to express complex proteins in a human-like manner is also predicted to promote product uptake in the coming years. There has been a surge in the of FDA-approved recombinant protein therapies. According to the National Institute of Health, the US Food and Drug Administration (FDA) approves more than 15 innovative recombinant protein treatments each year. Furthermore, the expiration of branded pharmaceuticals has prompted the development of biosimilars. As a result, the demand for cell line creation is increasing. The methotrexate (MTX) amplification method or the glutamine synthetase (GS) system is used by most biopharmaceutical businesses that create mammalian cell lines. Mammalian cell line cell clones are highly heterogeneous, and many cell clones must be screened to identify rare stable high producer cell clones. Several advances in mammalian cell line development have been made to make the screening process easier, making it the preferred source for cell line development. Furthermore, the need for cell line creation is expected to be fueled by enhanced cell engineering and expression methods to develop this source. There are roughly 4,000 mammalian cell lines available for biologics research and manufacture. As a result of advancements in mammalian cell lines, the segment is expected to grow steadily in the future.
Cell Line Development Market Geographical Share
North America region holds the largest market share of the global cell line development market
North America accounted for the majority of the share of the global cell line development market. The United States has a better healthcare infrastructure and the presence of major companies in the country are contributing to the dominance of this region. In addition, the US government's funding for accelerating research in the biotechnology and pharmaceutical industries has boosted the demand for cell line creation. Furthermore, the presence of many key players in North America is a major factor driving market growth.
However, The Asia-Pacific region is expected to rise rapidly in the global cell line development market. The Asia-Pacific regional market is expected to grow rapidly due to rising government and private-sector healthcare spending. In India, for example, the Department of Scientific and Industrial Research (DSIR)and Department of Science and Technology (DST), Department of Biotechnology (DBT) regulate and set guidelines for biotechnology products. These organizations provide guidelines for manufacturing or technology transfer and generate manpower for production and raise funds.
Cell Line Development Companies and Competitive Landscape
The cell line development market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include American Type Culture Collection, Lonza Group AG, Thermo Fisher Scientific Inc, GE Healthcare, Sigma Aldrich Corporation ,Selexis SA, Promega Corporation, Corning Inc, WuXiApp Tec Inc, Sartorious AG.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance in Oct 2019, ATCC (US) has introduced a portfolio of exosomes (extracellular vesicles) derived from human cells to be used as reference materials or standards in various research applications. Researchers' first two exosomes are derived from the A549 non-small cell lung cancer (NSCLC) cell line and hTERT-immortalized mesenchymal stem cells.
Key Developments
- In Oct 2019, The American Type Culture Collection has launched a mouse cell line authentication service (NIST). This collaboration has aided the corporation in expanding both its cell line business portfolio and its existing customer base.
- In Feb 2017, Lonza and Sanofi have formed strategic cooperation to create mammalian cell culture facilities in Switzerland to manufacture monoclonal antibodies. The company was able to expand regionally and generate more money due to this strategy.
- In 2018, Denali Therapeutics (US) and Lonza (Switzerland) have cooperated to research and manufacture biologic medicines using Lonza's GS Xceed cell line development technology. The major players engage in strategic partnerships, product launches, and joint ventures.
- In Sep 2020, Octapharma (Switzerland), a major manufacturer of human therapeutic proteins, selected Genedata Selector (Switzerland) as its key computational platform to expedite next-generation sequencing-based cell line development and cell culture optimization procedures. The partnership was carried out to save development time and improve efficiency.
- In November 2017, Lonza Group (Switzerland) launched a Multiplex Cell line culture that uses a GS Xceed Gene Expression System to test multiple drug candidates at an early developmental stage, saving 4 to 6 months that would otherwise be required in a traditional development program.
GE Healthcare
Overview: GE Healthcare's Edison intelligence platform enables physicians to make faster, more informed decisions via intelligent devices, data analytics, applications, and services.
Product Portfolio:
Promosome mammalian cell lines: Promosome's mammalian cell line creation technologies, which aim to boost protein expression in mammalian cells.
